Cellyan Biotechnology Co. Class AHKPD
13F holders, Q2 2026 (June 30)6holders +2
3new positions
1sold out
$0.43avg. 13F price*
At the end of Q2 2026, 6 institutions reported holding Cellyan Biotechnology Co. Class A (HKPD) in their 13F filings, up 2 from Q1 2026. 3 opened new positions and 1 sold out. The largest holders were StoneX Group Inc. ($52K), Jane Street Group, LLC ($19K) and HRT Financial LP ($15K).
- Company
- Cellyan Biotechnology Co. Class A
- CUSIP
- G6365B104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $48K |
| Exits | 1 | $6K |
All 13F filers, Q1 2026 → Q2 2026: 193,727 shares bought and 10,832 shares sold, net +182,895 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| StoneX Group Inc. | 0.00% | Add +159.7% | 102,310 | $52K |
| Jane Street Group, LLC | 0.00% | New | 49,087 | $19K |
| HRT Financial LP | 0.00% | New | 41,824 | $15K |
| XTX Topco Ltd | 0.00% | New | 38,930 | $15K |
| Clear Street Group Inc. | 0.00% | No change | 12,019 | $5K |
| UBS Group AG | 0.00% | Add +882.7% | 1,081 | $411 |
"% of holder's portfolio" is HKPD's weight in each manager's 13F, not the share of Cellyan Biotechnology Co. Class A the manager owns.